Aims And Background: Gastric and bladder metastases are rare in non-small-cell lung cancer (NSCLC) and the differential diagnosis with primary tumors requires an in-depth examination. KRAS gene mutations are the main oncogenic driver of lung adenocarcinoma in Caucasian patients, occurring in 25%-30% of cases, but their prognostic and predictive role is complex and not fully clarified. KRAS mutations in lung adenocarcinoma are considered negatively predictive for epidermal growth factor receptor tyrosine kinase inhibitors therapy as well as for adjuvant chemotherapy. In this report, the authors describe a case of lung adenocarcinoma harboring a codon 13 KRAS mutation detected in all the biopsies performed in unusual metastatic sites during an atypical disease course.
Conclusions: Recently, a different prognostic significance of various KRAS mutations in lung adenocarcinoma has been suggested. Further studies on rare biomolecular alterations to identify subgroups of patients with different prognostic/predictive characteristics are needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5301/tj.5000358 | DOI Listing |
J Proteome Res
January 2025
Department of Thoracic Surgery, Ningbo No.2 Hospital, Ningbo, 315010 Zhejiang, China.
Pharmacoeconomics
January 2025
Division of Pulmonology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Shengli Road, Tainan, 704, Taiwan.
Background And Objective: Approximately half of lung adenocarcinomas in East Asia harbor epidermal growth factor receptor (EGFR) mutations. EGFR testing followed by tissue-based next-generation sequencing (NGS), upfront tissue-based NGS, and complementary NGS approaches have emerged on the front line to guide personalized therapy. We study the cost effectiveness of exclusionary EGFR testing for Taiwanese patients newly diagnosed with advanced lung adenocarcinoma.
View Article and Find Full Text PDFBiochem Genet
January 2025
Department of Cardiac Function, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, Hubei, China.
Lung adenocarcinoma (LUAD) is characterized by its aggressive nature and resistance to treatment. FAM107A is a tumor suppressor gene that has been found to possess inhibitory effects in several cancers, but its role in LUAD remains unclear. This study investigated the role of FAM107A in regulating LUAD cell growth, invasion and aerobic glycolysis and also investigated the potential underlying mechanisms.
View Article and Find Full Text PDFAnticancer Drugs
February 2025
Department of Medical Oncology, Ankara Bilkent City Hospital, Medical Oncology Clinic.
Epidermal growth factor receptor (EGFR) mutations like the common L858R and exon 19 deletions are well studied, but rarer mutations like exon 19 insertions have received less attention. This case report describes a patient with this uncommon EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma. A 51-year-old male nonsmoker with metastatic lung adenocarcinoma and a rare EGFR exon 19 insertion mutation experienced disease progression on initial carboplatin-pemetrexed chemotherapy.
View Article and Find Full Text PDFFront Oncol
December 2024
Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Background: Leptomeningeal metastasis of gastric adenocarcinoma (LM-GC) is a rare and severe complication with a poor prognosis, its prognosis is significantly poorer than liver, lung, and peritoneal metastases. Studies on LM-GC have been limited to clinical case reports. Despite advances in systemic therapies, there is a lack of standardized treatment protocols for LM-GC due to its rarity and the challenges it presents.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!